Table 2 Treatment modalities and outcomes regarding tumor response and biochemical of male patients with prolactinomas/lactotroph PitNETs.
Overall cohort (n = 41) | Aggressive (n = 10) | Non-aggressive (n = 31) | P value | Age-adjusted P value | |
|---|---|---|---|---|---|
Treatment | |||||
Maximum weekly cabergoline dose (mg, mean ± SD) | 2.5 ± 2.0 | 2.9 ± 2.6 | 2.1 ± 1.5 | 0.005 | 0.001 |
Surgery (n, %) | 11 (26.8) | 6 (60.0) | 5 (16.1) | 0.005 | 0.005 |
Reoperation (n, %) | 3 (7.3) | 3 (30.0) | 0 | 0.002 | 0.010 |
Post-surgical radiotherapy (n, %) | 4 (9.8) | 4 (40.0) | 2 (6.5) | 0.004 | 0.004 |
Outcomes | |||||
Partial tumor control (n, %) | 15 (36.6) | 5 (50.0) | 10 (38.7) | 0.777 | 0.026 |
Partial biochemical control (n, %) | 36 (87.8) | 8 (80.0) | 28 (90.3) | 0.063 | 0.350 |
Controlled with medical therapy (n, %) | 27 (65.9) | 4 (40.0) | 23 (74.2) | 0.078 | 0.261 |
Last prolactin (ng/mL, median [IQR]) | 6.8 [24.05] | 31.3 [241.1] | 5.5 [12.4] | 0.041 | 0.004 |
Residual tumor (n, %) | 34 (82.9) | 8 (80.0) | 26 (83.9) | 0.742 | 0.217 |
Mortality (n, %) | 1 (2.4) | 1 (10.0) | 0 | 0.244 | 0.188 |
